Literature DB >> 18313376

Role of genetic background in determining phenotypic severity throughout postnatal development and at peak bone mass in Col1a2 deficient mice (oim).

Stephanie M Carleton1, Daniel J McBride, William L Carson, Carolyn E Huntington, Kristin L Twenter, Kristin M Rolwes, Christopher T Winkelmann, J Steve Morris, Jeremy F Taylor, Charlotte L Phillips.   

Abstract

Osteogenesis imperfecta (OI) is a genetically and clinically heterogeneous disease characterized by extreme bone fragility. Although fracture numbers tend to decrease post-puberty, OI patients can exhibit significant variation in clinical outcome, even among related individuals harboring the same mutation. OI most frequently results from mutations in type I collagen genes, yet how genetic background impacts phenotypic outcome remains unclear. Therefore, we analyzed the phenotypic severity of a known proalpha2(I) collagen gene defect (oim) on two genetic backgrounds (congenic C57BL/6J and outbred B6C3Fe) throughout postnatal development to discern the phenotypic contributions of the Col1a2 locus relative to the contribution of the genetic background. To this end, femora and tibiae were isolated from wildtype (Wt) and homozygous (oim/oim) mice of each strain at 1, 2 and 4 months of age. Femoral geometry was determined via muCT prior to torsional loading to failure to assess bone structural and material biomechanical properties. Changes in mineral composition, collagen content and bone turnover were determined using neutron activation analyses, hydroxyproline content and serum pyridinoline crosslinks. muCT analysis demonstrated genotype-, strain- and age-associated changes in femoral geometry as well as a marked decrease in the amount of bone in oim/oim mice of both strains. Oim/oim mice of both strains, as well as C57BL/6J (B6) mice of all genotypes, had reduced femoral biomechanical strength properties compared to Wt at all ages, although they improved with age. Mineral levels of fluoride, magnesium and sodium were associated with biomechanical strength properties in both strains and all genotypes at all ages. Oim/oim animals also had reduced collagen content as compared to Wt at all ages. Serum pyridinoline crosslinks were highest at two months of age, regardless of strain or genotype. Strain differences in bone parameters exist throughout development, implicating a role for genetic background in determining biomechanical strength. Age-associated improvements indicate that oim/oim animals partially compensate for their weaker bone material, but never attain Wt levels. These studies indicate the importance of genetic background in determining phenotypic severity, but the presence of the proalpha2(I) collagen gene defect and age of the animal are the primary determinants of phenotypic severity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18313376      PMCID: PMC2423326          DOI: 10.1016/j.bone.2007.12.215

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  47 in total

1.  Identification of collagen alpha1(I) trimer and normal type I collagen in a polyoma virus-induced mouse tumor.

Authors:  L Moro; B D Smith
Journal:  Arch Biochem Biophys       Date:  1977-07       Impact factor: 4.013

2.  Synthesis of type I homotrimer collagen molecules by cultured human lung adenocarcinoma cells.

Authors:  J H Rupard; S J Dimari; I Damjanov; M A Haralson
Journal:  Am J Pathol       Date:  1988-11       Impact factor: 4.307

3.  Collagen polymorphism in cultured rat kidney mesangial cells.

Authors:  M A Haralson; H R Jacobson; R L Hoover
Journal:  Lab Invest       Date:  1987-11       Impact factor: 5.662

4.  Collagen polymorphism: isolation and partial characterization of alpha 1(I)-trimer molecules in normal human skin.

Authors:  J Uitto
Journal:  Arch Biochem Biophys       Date:  1979-02       Impact factor: 4.013

Review 5.  Determination of hydroxyproline.

Authors:  H Stegemann; K Stalder
Journal:  Clin Chim Acta       Date:  1967-11       Impact factor: 3.786

6.  Transgenic mouse model of the mild dominant form of osteogenesis imperfecta.

Authors:  J Bonadio; T L Saunders; E Tsai; S A Goldstein; J Morris-Wiman; L Brinkley; D F Dolan; R A Altschuler; J E Hawkins; J F Bateman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

7.  Analysis of covariance using the rank transformation.

Authors:  W J Conover; R L Iman
Journal:  Biometrics       Date:  1982-09       Impact factor: 2.571

8.  Genetic heterogeneity in osteogenesis imperfecta.

Authors:  D O Sillence; A Senn; D M Danks
Journal:  J Med Genet       Date:  1979-04       Impact factor: 6.318

9.  Osteogenesis imperfecta after the menopause.

Authors:  C R Paterson; S McAllion; J L Stellman
Journal:  N Engl J Med       Date:  1984-06-28       Impact factor: 91.245

10.  The distribution of magnesium in developing rat incisor dentin.

Authors:  J Steinfort; F C Driessens; H J Heijligers; W Beertsen
Journal:  J Dent Res       Date:  1991-03       Impact factor: 6.116

View more
  25 in total

1.  Effect of food restriction and leptin supplementation on fetal programming in mice.

Authors:  Kathleen A Pennington; Jennifer L Harper; Ashley N Sigafoos; Lindsey M Beffa; Stephanie M Carleton; Charlotte L Phillips; Laura C Schulz
Journal:  Endocrinology       Date:  2012-07-09       Impact factor: 4.736

2.  Osteopontin regulates dentin and alveolar bone development and mineralization.

Authors:  B L Foster; M Ao; C R Salmon; M B Chavez; T N Kolli; A B Tran; E Y Chu; K R Kantovitz; M Yadav; S Narisawa; J L Millán; F H Nociti; M J Somerman
Journal:  Bone       Date:  2017-12-05       Impact factor: 4.398

3.  Zoledronate and Raloxifene combination therapy enhances material and mechanical properties of diseased mouse bone.

Authors:  Katherine M Powell; Cayla Skaggs; Alexis Pulliam; Alycia Berman; Matthew R Allen; Joseph M Wallace
Journal:  Bone       Date:  2019-06-21       Impact factor: 4.398

4.  Myostatin deficiency partially rescues the bone phenotype of osteogenesis imperfecta model mice.

Authors:  A K Oestreich; S M Carleton; X Yao; B A Gentry; C E Raw; M Brown; F M Pfeiffer; Y Wang; C L Phillips
Journal:  Osteoporos Int       Date:  2015-07-16       Impact factor: 4.507

Review 5.  New perspectives on osteogenesis imperfecta.

Authors:  Antonella Forlino; Wayne A Cabral; Aileen M Barnes; Joan C Marini
Journal:  Nat Rev Endocrinol       Date:  2011-06-14       Impact factor: 43.330

6.  Hindlimb Skeletal Muscle Function and Skeletal Quality and Strength in +/G610C Mice With and Without Weight-Bearing Exercise.

Authors:  Youngjae Jeong; Stephanie M Carleton; Bettina A Gentry; Xiaomei Yao; J Andries Ferreira; Daniel J Salamango; MaryAnn Weis; Arin K Oestreich; Ashlee M Williams; Marcus G McCray; David R Eyre; Marybeth Brown; Yong Wang; Charlotte L Phillips
Journal:  J Bone Miner Res       Date:  2015-05-14       Impact factor: 6.741

7.  Decreasing maternal myostatin programs adult offspring bone strength in a mouse model of osteogenesis imperfecta.

Authors:  Arin K Oestreich; William M Kamp; Marcus G McCray; Stephanie M Carleton; Natalia Karasseva; Kristin L Lenz; Youngjae Jeong; Salah A Daghlas; Xiaomei Yao; Yong Wang; Ferris M Pfeiffer; Mark R Ellersieck; Laura C Schulz; Charlotte L Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-07       Impact factor: 11.205

8.  Skeletal Response to Soluble Activin Receptor Type IIB in Mouse Models of Osteogenesis Imperfecta.

Authors:  Youngjae Jeong; Salah A Daghlas; Yixia Xie; Molly A Hulbert; Ferris M Pfeiffer; Mark R Dallas; Catherine L Omosule; R Scott Pearsall; Sarah L Dallas; Charlotte L Phillips
Journal:  J Bone Miner Res       Date:  2018-06-22       Impact factor: 6.741

9.  Skeletal muscle weakness in osteogenesis imperfecta mice.

Authors:  Bettina A Gentry; J Andries Ferreira; Amanda J McCambridge; Marybeth Brown; Charlotte L Phillips
Journal:  Matrix Biol       Date:  2010-07-06       Impact factor: 11.583

10.  Gender-dependence of bone structure and properties in adult osteogenesis imperfecta murine model.

Authors:  Xiaomei Yao; Stephanie M Carleton; Arin D Kettle; Jennifer Melander; Charlotte L Phillips; Yong Wang
Journal:  Ann Biomed Eng       Date:  2013-03-28       Impact factor: 3.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.